Status:
UNKNOWN
Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII
Lead Sponsor:
Osaka University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
ISHIHARA SANGYO KAISHA,LTD. Japan
Conditions:
Advanced Melanoma
Eligibility:
All Genders
20-85 years
Phase:
PHASE2
Brief Summary
This is a multi-center, open-labeled, non-randomized, single arm investigator-initiated trial to evaluate the safety and efficacy of GEN0101 and Pembrolizmub combination in patients with advanced mela...
Detailed Description
1\. Primary Objective \& Hypothesis 1. Objective: Efficacy of the combination therapy The combination therapy with intracutaneous injections of GEN0101 + intravenous infusions of Pembrolizumab is giv...
Eligibility Criteria
Inclusion
- Patient will be eligible for this trial if all the following apply:
- Patient has given written informed consent by themselves
- Patient aged 20 to 85 years at the time of informed consent
- Patient has histologically- or cytologically-confirmed melanoma
- Patient with a diagnosis of incurable and unresectable, Stage IIIC, IIID or Stage IV advanced melanoma, showing confirmed SD or unconfirmed PD over 12-week treatment with an anti-PD-1 antibody such as nivolumab or Pembrolizumab. To be assigned a status of SD, changes in tumor measurements must be confirmed by consecutive repeat evaluations that should be performed in 4 to 6 weeks after the criteria for response are first met over 12-week of an anti-PD-1 antibody treatment.
- Patient has a measurable tumor
- Patient has life expectancy of at least 12 weeks after the first dose of investigational product
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening
- Patient has met the following criteria of clinical laboratory tests at screening (1)White blood cell (WBC) count over 3,000/μL and neutrophil count over 1,500/μL (2)Platelet count over over 75,000/μL (3)Hemoglobin over 8.0 g/dL (4)AST and ALT ≤ 2.5 × upper limit of normal (ULN) (5)Total bilirubin ≤ 2 × ULN (6)Serum creatinine ≤ 2 × ULN
- LDH is not higher than the 2-fold of the upper limit of the institutional reference.
- A female patient of childbearing potential (a premenopausal woman, a woman with medically or drug-induced amenorrhea, and a woman with no history of sterilization), who has agreed to use appropriate contraception, e.g., the barrier method and a total abstinence, during the trial treatment until 3 months passed after completion of the trial treatment. A male patient who has agreed to use appropriate contraception, e.g., the barrier method and a total abstinence, during the above period.
Exclusion
- Patient will be excluded from participation if any of the following apply:
- Patient has brain metastases. Patients with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging\* (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
- Patient has showed positive reaction in a prick testing for GEN0101
- A patient who has the mutant BRAF gene in a tumor biopsy.
- A patient who has current pneumonitis.
- Patient concurrently has an active infection requiring systemic therapy.
- Patient has received other systemic anticancer therapy than an anti-PD-1 antibody therapy such as nivolumab, Pembrolizumab, or local IFN-beta therapy within 3 weeks before the time of informed consent (or within 6 weeks before the time of the informed consent for a patient who received nitrosourea or mitomycin C)
- Patient has received another unapproved drug other than anti-PD-L1 antibody within 4 weeks before the time of informed consent
- Patient has intraocular (uveal) melanoma
- Patient has or had another malignant tumor than melanoma. However, this criterion does not apply to a patient who has experienced neither recurrence nor metastasis for at least 5 years at the time of informed consent.
- Patient has received systemic corticosteroid or systemic immunosuppressant within 1 week before the first dose of investigational product. However, this criterion does not apply to a patient who has been on long-term (\>6-month) treatment at a low dose (equivalent to oral prednisolone under 10 mg/day) or who received prophylactic immunosuppressant against contrast media allergy.
- Patient has received a live vaccine within 30 days before registration
- Patient has enrolled in another clinical trial and received an investigational product within 4 months before the first dose of investigational product, or patient has intended to be enrolled in another clinical trial in parallel with this clinical trial
- A patient who has an active TB infection.
- Female patient is pregnant (including one with positive results from a pregnancy test at screening), lactating, or intending to become pregnant during participation in this trial and before 3 months have passed after completion of this trial. However, this criterion does not apply to a patient who will stop lactating (from the date of informed consent until 30 days passed after the last treatment). Of note, female patients should undergo a beta-HCG test to demonstrate pregnancy status. Male patient who does not agree to use appropriate contraception such as the barrier method and a total abstinence during this trial until 3 months passed after the completion of this trial. (Detailed method is described in 5.7 Contraception)
- Patient has psychiatric disease considered to be a potential concern from the viewpoints of follow-up and protocol adherence
- Patient had given autografting or allografting of organ or tissue (receiving an immunosuppressant)
- Patient has over 10%-shorter prothrombin time (PT) compared to lower limit of normal (LLN) or over 1.5-fold longer activated partial thromboplastin time (APTT) compared to ULN at screening
- Patient has showed positive reaction to any of HBs antigen, HCV antibody, HIV-1 antibody, or HIV-2 antibody at screening. However, even if it is positive for HCV antibody, it should not be excluded when HCV RNA test is negative.
- Patient is considered ineligible for this trial by the investigator or the sub-investigators
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT03818893
Start Date
March 1 2019
End Date
June 30 2022
Last Update
January 30 2019
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Nagoya University Hospital
Nagoya, Aichi-ken, Japan, 466-8550
2
Sapporo Medical University Hospital
Sapporo, Hokkaido, Japan, 060-8543
3
Kumamoto University Hospital
Kuramoto, Kumamoto, Japan, 860-8556
4
Shizuoka Cancer Center
Nakatogari, Shizuoka, Japan, 411-8777